ExodusPoint Capital Management’s Tyra Biosciences TYRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-41,026
Closed -$1.31M – 2194
2026
Q2
$1.31M Buy
41,026
+26,960
+192% +$892K 0.01% 986
2026
Q1
$539K Sell
14,066
-28,725
-67% -$930K ﹤0.01% 1175
2025
Q4
$1.12M Buy
+42,791
New +$786K 0.01% 953
2025
Q3
– Sell
-67,442
Closed -$645K – 2039
2025
Q2
$645K Buy
67,442
+37,207
+123% +$354K 0.01% 1079
2025
Q1
$281K Buy
+30,235
New +$391K ﹤0.01% 1244
2024
Q3
– Sell
-170,717
Closed -$2.73M – 2113
2024
Q2
$2.73M Sell
170,717
-101,433
-37% -$1.75M 0.02% 668
2024
Q1
$4.46M Buy
+272,150
New +$4.46M 0.03% 430

Other funds holding TYRA

ExodusPoint Capital Management's TYRA Position: Q3 2026 in Review

ExodusPoint Capital Management sold out of Tyra Biosciences (TYRA) in Q3 2026, closing a stake of 41,026 shares — an estimated $1.31M sold.

ExodusPoint Capital Management first reported a position in TYRA in Q1 2024 and held it in 7 quarters. The position peaked at $4.46M in Q1 2024. 155 funds tracked by Wall St. Rank hold TYRA as of Q3 2026.

  • ExodusPoint Capital Management reported no remaining Tyra Biosciences position as of Q3 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 41,026 Tyra Biosciences shares in Q3 2026, an estimated $1.31M.
  • ExodusPoint Capital Management first reported a position in Tyra Biosciences in Q1 2024 and held it in 7 quarters.
  • ExodusPoint Capital Management's Tyra Biosciences position peaked at $4.46M in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Tyra Biosciences as of Q3 2026.

Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.